Chilton Investment Co. LLC Has $27.89 Million Position in Becton Dickinson and Co (BDX)

Chilton Investment Co. LLC boosted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 1.6% in the first quarter, HoldingsChannel.com reports. The firm owned 111,668 shares of the medical instruments supplier’s stock after purchasing an additional 1,705 shares during the quarter. Chilton Investment Co. LLC’s holdings in Becton Dickinson and were worth $27,887,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the business. Vanguard Group Inc boosted its holdings in Becton Dickinson and by 1.3% in the 3rd quarter. Vanguard Group Inc now owns 21,666,262 shares of the medical instruments supplier’s stock worth $5,654,895,000 after buying an additional 283,433 shares during the last quarter. BlackRock Inc. raised its position in Becton Dickinson and by 1.9% in the fourth quarter. BlackRock Inc. now owns 19,384,283 shares of the medical instruments supplier’s stock valued at $4,367,665,000 after purchasing an additional 355,223 shares during the period. Oregon Public Employees Retirement Fund increased its position in shares of Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares during the period. Ronna Sue Cohen grew its stake in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Becton Dickinson and by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 3,208,583 shares of the medical instruments supplier’s stock worth $721,582,000 after purchasing an additional 223,215 shares in the last quarter. 85.24% of the stock is owned by hedge funds and other institutional investors.

Shares of NYSE BDX opened at $222.84 on Wednesday. The stock has a market capitalization of $60.34 billion, a PE ratio of 20.24, a price-to-earnings-growth ratio of 1.68 and a beta of 1.16. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.57 by $0.02. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. During the same period last year, the company earned $2.65 earnings per share. The firm’s revenue was down .6% compared to the same quarter last year. Analysts expect that Becton Dickinson and Co will post 11.69 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

In other news, CEO Vincent A. Forlenza sold 11,340 shares of the business’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the sale, the chief executive officer now directly owns 227,250 shares in the company, valued at $56,903,400. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Betty D. Larson sold 1,700 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $224.97, for a total value of $382,449.00. Following the sale, the executive vice president now owns 11,493 shares in the company, valued at $2,585,580.21. The disclosure for this sale can be found here. Insiders have sold 31,384 shares of company stock valued at $7,901,023 in the last three months. Insiders own 0.12% of the company’s stock.

BDX has been the subject of several analyst reports. Raymond James cut their price target on shares of Becton Dickinson and from $290.00 to $280.00 and set a “strong-buy” rating for the company in a report on Tuesday, March 19th. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Zacks Investment Research downgraded shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. Barclays raised their target price on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a research note on Monday, April 15th. Finally, KeyCorp reaffirmed an “overweight” rating and set a $262.00 price target (down previously from $273.00) on shares of Becton Dickinson and in a research note on Friday, May 10th. Six equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $255.31.

TRADEMARK VIOLATION WARNING: “Chilton Investment Co. LLC Has $27.89 Million Position in Becton Dickinson and Co (BDX)” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2019/05/15/chilton-investment-co-llc-has-27-89-million-position-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: Stock Selection – What is cash flow?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.